Clinical Trial Update: The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating an oral radiation sensitizer in newly diagnosed small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Radiation sensitizer (oral)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Small Cell, Small Cell Lung Cancer | Phase 2 | Status: COMPLETED